Abterra Bio uses machine learning to mine the human immune system to discover novel antibody therapeutics. Patients mount lasting antibody responses to infectious diseases and cancer. Our platform uses next-generation sequencing and mass spectrometry data to comprehensively map this antibody response, rapidly identifying better therapeutic antibodies. We’ve built an interdisciplinary team of data scientists and biologists to re-imagine how antibody therapeutics are developed.
(formerly Digital Proteomics)
Abterra Bio in the News
Meet Abterra Bio
Abterra Bio has developed a drug discovery platform that delivers the next generation of antibody therapeutics by directly mining the immune systems of real patients. Combining state of the art genomics, proteomics, and bioinformatics, Abterra Bio accesses the immune system at an unprecedented scale and delivers antibody drug candidates that are more effective.
Why is your company the best option to solve the problem you're solving?
Our team pioneered methods in antibody analysis, and we combine the needed expertise in immunology data generation and data analysis to deliver better antibody therapeutic candidates.
What nuggets of info make you interesting? Why do people care about what you're doing?
We have the ability to directly mine the human immune system, the original pharmaceutical company. Antibodies developed by humans have already been optimized and proven effective against disease, and therefore, make the best drugs.
BEHIND THE COMPANY
CEO/Founder: Natalie Castellana
What is your company's secret sauce?
We are the only company that focuses directly on the antibody protein which is the optimized end product of our immune response and the bioactive molecule that keeps us healthy in the face of disease.
Back to All Companies